Navigation Links
Threshold Pharmaceuticals Announces Multiple Presentations on,Oncology Pipeline at the 2007 American Association for Cancer,Research (AACR) Annual Meeting

REDWOOD CITY, Calif., April 16, 2007 /PRNewswire-FirstCall/ -- Threshold Pharmaceuticals, Inc. , today announced multiple presentations regarding its oncology pipeline, which includes two preclinical presentations on the Hypoxically Activated Prodrug, TH-302, and two research presentations from Threshold's Tubulin Inhibitor program. The presentations will take place at the 2007 American Association for Cancer Research (AACR) annual meeting being held April 14 - 18, 2007, at the Los Angeles Convention Center in Los Angeles, CA.

The following presentations will take place on Tuesday, April 17, 2007 from 8:00am to 12:00pm:

     Poster 3988: In Vivo Anti-Cancer Efficacy of a Hypoxia Activated Prodrug,

     TH-302

     Poster Session: Angiogenesis Inhibitors


     Poster 3985: Anti-Tumor Activity of a Hypoxia Activated Prodrug, TH-302,

     in Pancreatic and Prostate Orthotopic Models of Cancer

     Poster Session: Angiogenesis Inhibitors


     Poster 3984: A Novel Class of Tubulin Inhibitors that Exhibit Potent

     Antiproliferation and Vascular Targeting Activities

     Poster Session: Angiogenesis Inhibitors


     Poster 3965: 3-Aroylindazoles: Their Synthesis and Potential Use for

     Cancer Treatment

     Poster Session: Drug Discovery Design 1

Copies of the posters will be available on the Threshold website on Tuesday, April 17, 2007 at http://investor.thresholdpharm.com/calendar.cfm.

About Threshold Pharmaceuticals

Threshold is a biotechnology company focused on the discovery and development of small molecule therapeutics for the potential treatment of cancer. By selectively targeting abnormally-proliferating tumor cells, the Company's drug candidates are designed to be potentially more effective and less toxic to healthy tissues than conventional treatments. For additional inf ormation, please visit our website (www.thresholdpharm.com).

Forward-Looking Statements

Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Threshold's product candidates, and potential therapeutic uses and benefits of our product candidates. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward- looking statements. Potential risks and uncertainties include, but are not limited to, Threshold's ability to commence its anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Annual Report on Form 10-K, which was filed with the Securities Exchange Commission on March 15, 2007 and is available from the SEC's website (www.sec.gov) and on our website (www.thresholdpharm.com) under the heading "Investors." We do not intend to update any forward-looking statement made in this news release.

     Contact:

     Denise T. Powell

     Sr. Director, Corporate Communications

     Threshold Pharmaceuticals, Inc.

     650-474-8206

     

dpowell@thresholdpharm.com

CONTACT: Denise T. Powell, Sr. Director, Corporate Communications ofThreshold Pharmaceuticals, Inc., +1-650-474-8206, dpowell@thresholdpharm.com

Web site: http://www.thresholdpharm.com/

Ticker Symbol: (NASDAQ-NMS:THLD)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2017)... May 8, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., ... ("WRB"), a health care service center company based ... WRB specializes in relationship management programs for leading pharmaceutical ... WRB will join Envoy Health ... services for manufacturers, biotech firms, and other service companies. ...
(Date:5/4/2017)... Tenn. , May 4, 2017  A ... Infection Control, Ultraviolet-C light as a ... Tru-D SmartUVC,s ability to reduce bioburden on anesthesia ... bioburden reduction on high-touch, complex medical equipment surfaces ... surgical infections. "This study further validates ...
(Date:5/4/2017)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... announced that the Company,s first quarter 2017 financial results ... 11, 2017, and that the Company will host a ... that afternoon. Management will provide an overview of the ...
Breaking Medicine Technology:
(Date:5/27/2017)... Los Angeles, California (PRWEB) , ... May 26, 2017 , ... ... Canadian senior citizens who visit a doctor for colds or respiratory issues that are ... note that excessive time pressure on doctors may be largely responsible for the problem ...
(Date:5/27/2017)... Rosa, CA (PRWEB) , ... May 27, 2017 , ... ... cause for concern, but a new study from the Osteoarthritis Initiative shows ... to developing knee osteoarthritis. Knowing this in advance may give doctors the opportunity to ...
(Date:5/26/2017)... Fairfax, VA (PRWEB) , ... May 26, 2017 ... ... is pleased to announce a new educational seminar to focus on current legislative ... Regulatory News(LEARN) seminar will begin at 1 p.m. Sunday, Sept. 10, and will ...
(Date:5/26/2017)... ... 26, 2017 , ... Boar’s Head Brand®, one of the ... Day entertaining that are sure to satisfy your guests’ flavor cravings, while adding ... cheeses featured in these refreshingly balanced recipes are packed with flavor, creating the ...
(Date:5/26/2017)... ... May 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... focusing on the Peace Agreements being discussed by President Donald Trump and the rest ... to try to speed up peace talks in the continuous battle between Israel and ...
Breaking Medicine News(10 mins):